CY1118680T1 - Φαρμακευτικη συνθεση - Google Patents

Φαρμακευτικη συνθεση

Info

Publication number
CY1118680T1
CY1118680T1 CY20171100079T CY171100079T CY1118680T1 CY 1118680 T1 CY1118680 T1 CY 1118680T1 CY 20171100079 T CY20171100079 T CY 20171100079T CY 171100079 T CY171100079 T CY 171100079T CY 1118680 T1 CY1118680 T1 CY 1118680T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical composition
subjects
compounds
formula
treatment
Prior art date
Application number
CY20171100079T
Other languages
English (en)
Inventor
Mark Spyvee
Takashi Satoh
Jonathan Eric Carlson
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of CY1118680T1 publication Critical patent/CY1118680T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις του Τύπου (I), μαζί με φαρμακευτικές συνθέσεις που περιέχουν τις ίδιες, και μεθόδους χρήσης σε υποκείμενα που έχουν ανάγκη θεραπείας.
CY20171100079T 2010-09-21 2017-01-19 Φαρμακευτικη συνθεση CY1118680T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38478110P 2010-09-21 2010-09-21
PCT/US2011/051163 WO2012039972A1 (en) 2010-09-21 2011-09-12 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CY1118680T1 true CY1118680T1 (el) 2017-07-12

Family

ID=44674894

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100079T CY1118680T1 (el) 2010-09-21 2017-01-19 Φαρμακευτικη συνθεση

Country Status (30)

Country Link
US (2) US8686018B2 (el)
EP (2) EP3061751A1 (el)
JP (1) JP5956448B2 (el)
KR (1) KR101911105B1 (el)
CN (1) CN103097358B (el)
AU (1) AU2011305872B2 (el)
BR (1) BR112013002484B1 (el)
CA (1) CA2806121C (el)
CL (1) CL2013000675A1 (el)
CY (1) CY1118680T1 (el)
DK (1) DK2619182T3 (el)
ES (1) ES2610185T3 (el)
HR (1) HRP20170042T1 (el)
HU (1) HUE031408T2 (el)
IL (1) IL224288A (el)
LT (1) LT2619182T (el)
ME (1) ME02575B (el)
MX (1) MX2013003162A (el)
MY (1) MY162146A (el)
NZ (1) NZ606629A (el)
PE (1) PE20131343A1 (el)
PL (1) PL2619182T3 (el)
PT (1) PT2619182T (el)
RS (1) RS55566B1 (el)
RU (1) RU2606510C2 (el)
SG (1) SG188188A1 (el)
SI (1) SI2619182T1 (el)
SM (1) SMT201700008B (el)
UA (1) UA113499C2 (el)
WO (1) WO2012039972A1 (el)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
DK3009426T3 (en) * 2013-06-12 2018-05-28 Kaken Pharma Co Ltd 4-ALKYNYL-IMIDAZOLE DERIVATIVE AND MEDICINE COMPREHENSIVE AS AN ACTIVE INGREDIENT
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
CN106572993B (zh) * 2014-05-23 2019-07-16 卫材R&D管理有限公司 Ep4拮抗剂在制备治疗癌症的药物中的应用
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
CN108368127B (zh) 2015-07-23 2020-12-11 武田药品工业株式会社 化合物及其作为ep4受体拮抗剂的用途
BR112018007664B1 (pt) 2015-10-16 2023-12-19 Eisai R&D Management Co., Ltd Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
PT3625224T (pt) 2017-05-18 2021-10-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-substituídos
AU2018269666B2 (en) 2017-05-18 2022-02-03 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
TW201900178A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之嘧啶衍生物
CN108929281B (zh) * 2017-05-27 2021-12-24 华东师范大学 三氮唑类化合物及其合成方法和应用
EP3749323A4 (en) * 2018-02-05 2021-11-03 Shenzhen Ionova Life Science Co., Ltd. HETEROBICYCLIC CARBOXYLIC ACIDS TO TREAT CANCER OR INFLAMMATORY DISEASES
CN113354585A (zh) * 2020-03-04 2021-09-07 湖北生物医药产业技术研究院有限公司 新型ep4拮抗剂的合成及其在癌症和炎症中的用途
WO2022037601A1 (zh) * 2020-08-18 2022-02-24 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료
TW202227089A (zh) 2020-11-30 2022-07-16 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
EP4286371A1 (en) * 2021-01-28 2023-12-06 Shenzhen Zhongge Biological Technology Co., Ltd. Pyrazolamide derivative, preparation method therefor, and application thereof
TW202328073A (zh) * 2021-09-03 2023-07-16 大陸商武漢人福創新藥物研發中心有限公司 Ｅｐ４拮抗劑化合物及其鹽、多晶型及其製備方法和用途
CN115364222A (zh) * 2021-09-09 2022-11-22 首都医科大学附属北京地坛医院 Ep4受体抑制剂治疗肝纤维化的应用
WO2023122289A1 (en) 2021-12-23 2023-06-29 Eisai R&D Management Co., Ltd. Crystalline salt form of ep4 antagonist
CN116887817A (zh) * 2021-12-30 2023-10-13 杭州阿诺生物医药科技有限公司 一种固体药物组合物
WO2024027599A1 (zh) * 2022-08-04 2024-02-08 杭州阿诺生物医药科技有限公司 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0421671A (ja) * 1990-05-16 1992-01-24 Mitsubishi Kasei Corp ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
AU2003285012A1 (en) 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
FR2847160A1 (fr) 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
KR100747401B1 (ko) * 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물
GT200500013A (es) 2004-01-23 2005-08-10 Amidas herbicidas
CN1950334A (zh) * 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
AU2005238291A1 (en) 2004-05-04 2005-11-10 Pfizer Inc. Substituted methyl aryl or heteroaryl amide compounds
US8952176B2 (en) 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
WO2006134318A1 (en) * 2005-06-11 2006-12-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
AU2006316087B2 (en) 2005-11-21 2011-03-10 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I
JP5218737B2 (ja) * 2006-02-06 2013-06-26 大正製薬株式会社 スフィンゴシン−１−リン酸結合阻害物質
WO2007143825A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
JP5259592B2 (ja) 2006-08-11 2013-08-07 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体
EP2101751A1 (en) 2006-12-15 2009-09-23 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
JP5301469B2 (ja) 2007-02-26 2013-09-25 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
US7560936B1 (en) 2007-04-24 2009-07-14 Integrated Device Technology, Inc. Method and apparatus for ground bounce and power supply bounce detection
AU2008263883B2 (en) 2007-06-15 2014-03-13 Basf Se Method for producing difluoromethyl-substituted pyrazole compounds
CA2692265A1 (en) 2007-07-03 2009-01-08 Astellas Pharma Inc. Amide compounds
MY154668A (en) * 2007-07-19 2015-07-15 Lundbeck & Co As H 5-membered heterocyclic amides and related compounds
AR067744A1 (es) 2007-07-31 2009-10-21 Bayer Cropscience Sa Derivados fungicidas de (hetero) aril- metilen -n- cicloalquil carboxamida condensados de 6 elementos con n
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CA2722811C (en) * 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
EP2565191B1 (en) 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
JP2011529866A (ja) 2008-08-01 2011-12-15 バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト 殺菌剤ｎ−シクロアルキル−ｎ−ビフェニルメチル−カルボキサミド誘導体
WO2010019796A1 (en) * 2008-08-14 2010-02-18 Chemietek, Llc Heterocyclic amide derivatives as ep4 receptor antagonists
AU2009295308A1 (en) 2008-09-25 2010-04-01 Merck Canada Inc. Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists

Also Published As

Publication number Publication date
PL2619182T3 (pl) 2017-03-31
SG188188A1 (en) 2013-04-30
HRP20170042T1 (hr) 2017-03-10
JP5956448B2 (ja) 2016-07-27
MX2013003162A (es) 2013-05-06
DK2619182T3 (en) 2017-01-30
ES2610185T3 (es) 2017-04-26
US20140155452A1 (en) 2014-06-05
RS55566B1 (sr) 2017-05-31
KR101911105B1 (ko) 2018-10-23
SI2619182T1 (sl) 2017-03-31
AU2011305872A1 (en) 2013-01-31
RU2606510C2 (ru) 2017-01-10
ME02575B (me) 2017-06-20
HUE031408T2 (en) 2017-07-28
PT2619182T (pt) 2017-01-17
US20130237578A1 (en) 2013-09-12
CL2013000675A1 (es) 2013-07-05
CN103097358A (zh) 2013-05-08
UA113499C2 (xx) 2017-02-10
NZ606629A (en) 2015-03-27
LT2619182T (lt) 2017-01-25
CA2806121A1 (en) 2012-03-29
EP3061751A1 (en) 2016-08-31
AU2011305872B2 (en) 2015-03-26
CA2806121C (en) 2018-10-09
US9000024B2 (en) 2015-04-07
SMT201700008B (it) 2017-03-08
CN103097358B (zh) 2015-04-08
EP2619182B1 (en) 2016-11-09
MY162146A (en) 2017-05-31
KR20130099008A (ko) 2013-09-05
RU2013118209A (ru) 2014-10-27
US8686018B2 (en) 2014-04-01
EP2619182A1 (en) 2013-07-31
PE20131343A1 (es) 2013-11-18
BR112013002484B1 (pt) 2021-10-13
JP2013538825A (ja) 2013-10-17
IL224288A (en) 2015-02-26
WO2012039972A1 (en) 2012-03-29
BR112013002484A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1121120T1 (el) Αρυλ- ή ετεροαρυλ-υποκατεστημενες ενωσεις βενζολιου
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1119684T1 (el) Αντι-ιικες ενωσεις
CY1119245T1 (el) Φαρμακευτικη συνθεση καρβετοκινης
CY1120438T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει μυο-ινοσιτολη και d-κιρο-ινοσιτολη
UA114087C2 (xx) Похідні піридину
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CY1114988T1 (el) Βενζοδιαζεπινη αναστολεας bromodomain
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1121736T1 (el) Άλατα aramchol
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491505A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2013011922A (es) Compuestos de benceno substituido.
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
CY1117705T1 (el) Νεες ενωσεις διυποκατεστημενης 3,4-διαμινο-3-κυκλοβουτενο-διονης-1,2 για χρηση στην θεραπεια προκαλουμενων απο χημειοκινη ασθενειων
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства